author-photo

Jung-Min Lee

National Institutes of Health

62

Papers

2203

Citations

Citation Trend

Filter By

Papers (42) Sort By

Journal Conference Others

Update on PARP Inhibitors in Breast Cancer

2018 Current Treatment Options in Oncology
Show All
- Source
- Cite
- Save
Citations (48)
A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (27)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

2018 Nature Communications
Show All
- Source
- Cite
- Save
Citations (159)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

2018 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (112)
Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab

2018 BMC Pulmonary Medicine
Show All
- Source
- Cite
- Save
Citations (4)
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (13)
Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women’s cancers

2017 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (5)
Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)